

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number  
**WO 02/072881 A3**

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68, 1/70
- (21) International Application Number: PCT/EP02/02600
- (22) International Filing Date: 6 March 2002 (06.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
01200855.3 7 March 2001 (07.03.2001) EP
- (71) Applicant (*for all designated States except US*):  
**BIOMERIEUX B.V.** [NL/NL]; Boseind 15,, NL-5280  
AB Boxtel (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DEIMAN, Birgit, Alberta, Louisa, Maria** [NL/NL]; Buitenerf 225, NL-4824 HG Breda (NL). **FRANTZEN, Inge, Marjolein** [NL/NL]; Broekestynlaan 42, NL-5709 RG Helmond (NL). **STRIJP, Arnoldina, Margaretha, Wilhelmina** [NL/NL]; Maastrichtseweg 97, NL-5215 AG Den Bosch (NL).
- (74) Agent: **VAN SOMEREN, Petronella, Francisca, Hendrika, Maria**; Arnold- Siedsma, P.O. Box 18558, 2502 EN The Hague (NL).
- (81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
30 October 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR THE AMPLIFICATION AND DETECTION OF HBV DNA USING A TRANSCRIPTION BASED AMPLIFICATION

WO 02/072881 A3

(57) Abstract: The present invention provides a method for the transcription based amplification of a target HBV nucleic acid sequence starting from HBV DNA optionally present in a sample, comprising the steps of, - incubating the sample, suspected to contain HBV, in an amplification buffer with one or more restriction enzymes capable of cleaving the HBV DNA at a selected restriction site, said restriction enzyme creating a defined 3' end of the said HBV DNA strand(s), a promotor-primer, said promotor-primer having a 5' region comprising the sequence of a promotor recognized by a DNA-dependent RNA polymerase and a 3' region complementary to the define 3' end of the DNA strand, a second or reverse primer, having the opposite polarity of the promotor-primer and comprising the 5' end of the said target sequence, and in case of HBV ssDNA as the target sequence, a restriction primer, - maintaining the thus created reaction mixture under the appropriate conditions for a sufficient amount of time for a digestion by the restriction enzyme to take place, - subjecting the sample thus obtained to a heat treatment at a temperature and time sufficient to inactivate the restriction enzyme and/or to render at least partially a double strand single stranded, - adding the following reagents to the sample: an enzyme having RNA dependent DNA polymerase activity, an enzyme having DNA dependent DNA polymerase activity, an enzyme having Rnase H activity, an enzyme having RNA polymerase activity, and - maintaining the thus created reaction mixture under the appropriate conditions to a sufficient amount of time for the amplification to take place.

# INTERNATIONAL SEARCH REPORT

Internatl. Application No

PCT/EP 02/02600

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 C12Q1/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, EMBL, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 04340 A (CAMBRIDGE BIOTECH CORP) 4 April 1991 (1991-04-04)	1-10,21
Y	page 2, line 18-32 page 8, line 6-18 page 19, line 3-8 page 25, line 26 -page 32, line 15 page 39, line 29-33 page 42, line 15 -page 44, line 15	11-20
Y	US 5 981 179 A (DELAROSA ABEL ET AL) 9 November 1999 (1999-11-09) page 3, line 28-38 column 9, line 50 -column 10, line 6; figures 5,6; examples 1,5	9-20
Y	US 5 679 510 A (RAY BRYAN L ET AL) 21 October 1997 (1997-10-21) column 12, line 41 -column 13, line 29	9-20
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

10 June 2003

Date of mailing of the international search report

18/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Bradbrook, D

## INTERNATIONAL SEARCH REPORT

Internat .pplication No  
PCT/EP 02/02600

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FUJIYAMA ET AL: "Cloning and structural analyses of hepatitis B virus DNAs, subtype adr" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 13, 1983, pages 4601-4610, XP002140255 ISSN: 0305-1048 figures 1,2 ----	12-21
A	US 5 736 334 A (SPIES UWE) 7 April 1998 (1998-04-07) SEQ ID NOs 4-6,11,12,22,23,32 table A ----	12-21
A	DATABASE EMBL 'Online! Acc.no E25735, 22 February 2001 (2001-02-22) XP002183509 abstract ----	19
A	EP 0 397 269 A (AKZO NV) 14 November 1990 (1990-11-14) the whole document ----	1-10
A	WO 99 25868 A (AKZO NOBEL NV ;GEMEN BOB VAN (NL); SCHUKKINK ADRIANA FREDERICKE (N) 27 May 1999 (1999-05-27) cited in the application page 5, line 30 -page 7, line 34; claims 1-9 ----	1-21
A	KIEVITS T ET AL: "NASBATM ISOTHERMAL ENZYMATIC IN VITRO NUCLEIC ACID AMPLICIFACTION OPTIMIZED FOR THE DIAGNOSIS OF HIV-1 INFECTION" JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 35, no. 3, 1 December 1991 (1991-12-01), pages 273-286, XP000608751 ISSN: 0166-0934 the whole document ----	1-21
E	WO 02 070735 A (FRANTZEN INGE MARJOLEIN ;AKZO NOBEL NV (NL); DEIMAN BIRGIT ALBERTA) 12 September 2002 (2002-09-12) the whole document -----	1-21

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No  
PCT/EP 02/02600

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9104340	A	04-04-1991	WO 9104340 A1	04-04-1991
US 5981179	A	09-11-1999	US 6228578 B1	08-05-2001
			AU 711130 B2	07-10-1999
			AU 7072696 A	01-04-1997
			CA 2205353 A1	20-03-1997
			DE 69625461 D1	30-01-2003
			EP 0792376 A1	03-09-1997
			JP 11500628 T	19-01-1999
			US 6027897 A	22-02-2000
			WO 9710364 A1	20-03-1997
			US 6136535 A	24-10-2000
			US 2002012936 A1	31-01-2002
US 5679510	A	21-10-1997	AU 4652696 A	24-07-1996
			CA 2209523 A1	11-07-1996
			EP 0800588 A1	15-10-1997
			JP 10511852 T	17-11-1998
			WO 9621043 A1	11-07-1996
			AU 679228 B2	26-06-1997
			AU 6714194 A	21-11-1994
			CA 2159716 A1	10-11-1994
			EP 0691828 A1	17-01-1996
			JP 8509613 T	15-10-1996
			WO 9424959 A1	10-11-1994
			US 5663069 A	02-09-1997
US 5736334	A	07-04-1998	AU 7326494 A	13-02-1995
			CA 2167056 A1	26-01-1995
			EP 0785996 A1	30-07-1997
			JP 9501829 T	25-02-1997
			WO 9502690 A1	26-01-1995
EP 0397269	A	14-11-1990	AT 118549 T	15-03-1995
			AU 641159 B2	16-09-1993
			AU 5487790 A	15-11-1990
			CA 2016358 A1	10-11-1990
			DE 69016826 D1	23-03-1995
			DE 69016826 T2	08-06-1995
			DK 397269 T3	29-05-1995
			EP 0397269 A1	14-11-1990
			ES 2070995 T3	16-06-1995
			FI 102387 B1	30-11-1998
			IE 66597 B1	24-01-1996
			JP 2839639 B2	16-12-1998
			JP 3180184 A	06-08-1991
			KR 185376 B1	01-04-1999
			US 5466586 A	14-11-1995
			ZA 9003453 A	27-02-1991
WO 9925868	A	27-05-1999	AU 755395 B2	12-12-2002
			AU 1754799 A	07-06-1999
			CA 2309625 A1	27-05-1999
			WO 9925868 A1	27-05-1999
			EP 1032710 A1	06-09-2000
			JP 2001523469 T	27-11-2001
			US 6312928 B1	06-11-2001
			ZA 9809950 A	04-05-1999

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No  
PCT/EP 02/02600

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 02070735 A	12-09-2002	WO 02070735 A2	12-09-2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number  
**WO 02/072881 A2**

- (51) International Patent Classification<sup>7</sup>: **C12Q 1/68** (74) Agent: **HERMANS, Franciscus, G., M.**; P.O. Box 20, NL-5340 BH Oss (NL).
- (21) International Application Number: **PCT/EP02/02600**
- (22) International Filing Date: **6 March 2002 (06.03.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**01200855.3** **7 March 2001 (07.03.2001)** **EP**
- (71) Applicant (*for all designated States except US*): **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DEIMAN, Birgit, Alberta, Louisa, Maria** [NL/NL]; Buitenerf 225, NL-4824 HG Breda (NL). **FRANTZEN, Inge, Marjolein** [NL/NL]; Broekestynlaan 42, NL-5709 RG Helmond (NL). **STRIJP, Arnoldina, Margaretha, Wilhelmina** [NL/NL]; Maastrichtseweg 97, NL-5215 AG Den Bosch (NL).
- (81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR THE AMPLIFICATION AND DETECTION OF HBV DNA USING A TRANSCRIPTION BASED AMPLIFICATION

(57) Abstract: The present invention provides a method for the transcription based amplification of a target HBV nucleic acid sequence starting from HBV DNA optionally present in a sample, comprising the steps of, - incubating the sample, suspected to contain HBV, in an amplification buffer with one or more restriction enzymes capable of cleaving the HBV DNA at a selected restriction site, said restriction enzyme creating a defined 3' end of the said HBV DNA strand(s), a promotor-primer, said promotor-primer having a 5' region comprising the sequence of a promotor recognized by a DNA-dependent RNA polymerase and a 3' region complementary to the define 3' end of the DNA strand, a second or reverse primer, having the opposite polarity of the promotor-primer and comprising the 5' end of the said target sequence, and in case of HBV ssDNA as the target sequence, a restriction primer, - maintaining the thus created reaction mixture under the appropriate conditions for a sufficient amount of time for a digestion by the restriction enzyme to take place, - subjecting the sample thus obtained to a heat treatment at a temperature and time sufficient to inactivate the restriction enzyme and/or to render at least partially a double strand single stranded, - adding the following reagents to the sample: an enzyme having RNA dependent DNA polymerase activity, an enzyme having DNA dependent DNA polymerase activity, an enzyme having RNase H activity, an enzyme having RNA polymerase activity, and - maintaining the thus created reaction mixture under the appropriate conditions to a sufficient amount of time for the amplification to take place.

WO 02/072881 A2

**Method for the amplification and detection of HBV DNA using a transcription based amplification.**

The present invention is directed to a transcription based amplification method for the  
5 amplification of HBV DNA .

Nucleic acid amplification methods are used in the field of molecular biology and  
recombinant DNA technology. These methods are used to increase the number of  
copies of a particular nucleic acid sequence, present in small amounts and often in an  
10 environment in which a wide variety of other nucleic acid sequences, both RNA and  
DNA, are also present. In particular, nucleic acid amplification methods are used to  
facilitate the detection or quantification of nucleic acid and are important for diagnosing  
for example infectious diseases, inherited diseases and various types of cancer. Nucleic  
acid amplification methods have also found their applications in other fields where  
15 samples are investigated in which nucleic acid may be present in minute amounts, such  
as forensic sciences, archeology or to establish paternity.

Several nucleic acid amplification techniques are known based on different mechanisms  
of action. One method for the amplification of nucleic acid is known as the "Polymerase  
Chain Reaction" (PCR) is described in European patent applications EP 200362 and EP  
20 201148.

The present invention is concerned with a different class of nucleic acid amplification  
methods namely the "transcription based amplification techniques". With these methods  
multiple RNA copies are obtained from a DNA template that comprises a functional  
25 promoter recognized by the RNA polymerase. Said RNA copies are used as target from  
which new DNA templates are obtained etc. Gingeras et al. in WO88/10315 and Burg et  
al. in WO89/1050 have described such methods. Isothermal transcription based  
amplification techniques have been described by Davey et al. in EP 323822 (relating to  
the NASBA method), by Gingeras et al. in EP 373960 and by Kacian et al. in EP  
30 408295. Transcription based amplification reactions may also be performed with  
thermostable enzymes. Transcription based amplifications are usually carried out at a  
temperature around 41 degrees Celsius. Thermostable enzymes allow the reaction to be  
carried out at more elevated temperatures. Such a thermostable method is described in  
EP 682121 filed in the name of Toyo Boseki KK.

The methods as described in EP 323822, EP 373960 and EP 408295 are isothermal  
continuous methods. With these methods four enzyme activities are required to achieve  
amplification: an RNA dependent DNA polymerase activity, an DNA dependent DNA  
polymerase activity, an RNase (H) activity and an RNA polymerase activity. Some of  
these activities can be combined in one enzyme, so usually only 2 or 3 enzymes are  
35 necessary. Reverse transcriptase such as AMV (Avian Myoblastosis Virus) or MMLV  
(Moloney Murine Leukemia Virus) reverse transcriptase have both RNA- and DNA  
40

dependent DNA polymerase activity but also an inherent RNase H activity. In addition an RNase may be added to the reaction mixture of a transcription based amplification reaction, such as E. coli RNase H.

DNA dependent RNA polymerases synthesize multiple RNA copies from a DNA

5 template including a promoter recognized by the RNA polymerase. Examples of RNA polymerases are polymerases from E. coli and bacteriophages T7, T3 and SP6. An example of an RNA polymerase commonly used with transcription based amplification methods is T7 polymerase. Thus the promoter that is incorporated in the template used to produce multiple copies of RNA would then be the T7-promoter. Usually the template  
10 comprising the promoter has to be created starting from the nucleic acid comprising the target sequence. Said nucleic acid may be present in the starting material that is used as input for the amplification reaction. The nucleic acid present in the starting material will usually contain the target sequence as part of a much longer sequence. Additional nucleic acid sequences may be present on both the 3'- and the 5'-end of the target  
15 sequence. The amplification reaction can be started by bringing together this nucleic acid from the starting material, the appropriate enzymes that together provide the above mentioned activities and at least one, but usually two, oligonucleotide(s). At least one of these oligonucleotides should comprise the sequence of the RNA polymerase promoter. Transcription based amplification methods are particularly useful if the input material is  
20 single stranded RNA, although single or double stranded DNA can likewise be used as input material. When a transcription based amplification method is practiced on a sample with single stranded RNA with additional sequences on both the 3'-end and the 5' end of the target sequence a pair of oligonucleotides that is conveniently used with the methods as described in the prior art would consist of:

- 25 - a first oligonucleotide (usually referred to as "promoter-primer" or "forward-primer") that is capable of hybridizing to the 3'-end of the target sequence, which oligonucleotide has the sequence of a promoter (preferably the T7 promoter) attached to its 5' end (the hybridizing part of this oligonucleotide has the opposite polarity as the target RNA used as input material).
- 30 - a second oligonucleotide (usually referred to as "reverse primer") which comprises the 5' end of the target sequence (this oligonucleotide has the same polarity as the target RNA).

When such a pair of oligonucleotides, together with all enzymes having the appropriate activities, and a sufficient supply of the necessary ribonucleotides and deoxy-

35 ribonucleotides are put together in one reaction mixture and are kept under the appropriate conditions (that is, under the appropriate buffer conditions and at the appropriate temperature) for a sufficient period of time an isothermal continuous amplification reaction will start. Many variants of the above theme have been described in the prior art. A transcription based amplification reaction comprises the synthesis of  
40 single stranded RNA transcripts from a template comprising a promoter (e.g. the T7 promoter) that is recognized by an RNA polymerase (e.g. T7 RNA polymerase). A



forward primer, comprising the promoter sequence, serves as a primer to initiate the synthesis of a strand of DNA complementary to the target RNA.

The primer will be extended by the activity of RNA dependent DNA polymerase. The RNA-cDNA hybrid formed will be degraded by RNase H. This enables the hybridization of the specific reverse primer to the cDNA. Extension of this primer by RNA dependent DNA polymerase up to the 5' end of the cDNA results in the formation of a double-stranded promoter sequence, whereby the promoter sequence that was part of the forward primer is used as a template. This double stranded promoter will then be used by the DNA dependent RNA polymerase to produce many new RNA molecules that are complementary to the target RNA. After this initiation phase, the amplification enters a cyclic phase.

In practice, the whole sequence of events, starting from the single stranded RNA in the sample, will take place as soon as all ingredients are put together, and the mixture is brought to the appropriate temperature for the enzymes to be all active. The practitioner of the method need not to intervene to accomplish any of these steps.

As explained above, transcription based amplification methods are particularly useful for amplifications that start from single stranded RNA. The starting material containing the nucleic acid to be amplified may not contain the target nucleic acid as RNA of a defined length. When a transcription based amplification method is performed on starting material comprising the target sequence only as double stranded DNA, either circular or linear, the DNA would have to be converted to single stranded nucleic acid. This can be achieved by separating the strands of the double stranded DNA by applying an elevated temperature (up to a 100 degrees Celsius). The first of the oligonucleotides used as primers in the amplification may then anneal to one of the single strands. The enzymes used with current transcription based amplification methods cannot withstand such a high temperature and consequently can only be added after the DNA strands have been separated. When one of the oligonucleotides anneals to a single strand DNA and is elongated, double stranded DNA is created again, and the reaction mixture would have to be subjected to an elevated temperature sufficiently high to melt the double stranded DNA into its separated strands again. Again the enzymes would be inactivated and new enzymes are to be added after the heat step has been applied. The second oligonucleotide can now be added and anneal to the strand that was created from the elongated first oligonucleotide in the first step. As one of the oligonucleotides includes a 5' promoter sequence of a DNA dependent RNA polymerase (see above), a double stranded DNA template including a double stranded functional promoter is obtained, from which a first step of RNA production can take place. The resulting RNA transcripts may enter the cyclic phase of the amplification and the process can further be isothermal.

From the above it is evident that starting a transcription based amplification method from double stranded DNA can be a tedious process. It requires several specific actions to be

taken by the practitioner; the sample has to be heated and cooled repeatedly and enzymes have to be replenished after each heating step.

5 Some research has already gone into the developments of transcription based amplification methods that can start from dsDNA, avoiding the tedious procedure described above to convert the dsDNA into ssRNA that can be used as input for the cyclic isothermal transcription based amplification.

10 A rather simple transcription based amplification method for dsDNA has been disclosed in WO9925868.

According to the method described in WO9925868 dsDNA in a sample can be amplified by means of a transcription based amplification protocol directly, without any heat treatment step [of over 90 C] at all, or –in a preferred embodiment- with only one initial heating step. dsDNA, that is relatively short, is to be preferred in this method. Actually,  
15 the method does not differ essentially from a conventional transcription based amplification protocol to amplify ssRNA.

Alternatively, the double stranded DNA in the starting material can be transcribed into RNA before the start of the amplification. Such an extra step can be based on an  
20 enzyme, for instance E. coli RNA polymerase, that transcribes the double stranded DNA into RNA without the presence of a promoter sequence, also referred to as a polymerase binding site. Such a process of extra steps to facilitate the amplification of double stranded DNA by transcription based amplification methods has been described in PCT patent application no. WO9602668. The extra steps described in this procedure  
25 do not only include extra handling steps and handling time, but also the use of additional ingredients, i.e. the E. coli RNA polymerase.

Another way of preparing suitable templates for transcription based amplification methods for dsDNA is described in EP 397269.

30 In this patent a method is described whereby dsDNA is pretreated with a restriction enzyme. After treatment with the restriction enzyme only one heat separation step is needed to create single stranded DNA (ssDNA). With this method a forward primer (promoter-primer) is used that has a 3' part including a sequence that is complementary to the exact 3' end of one of the single strands of DNA and a 5' end including a promoter  
35 sequence recognized by a RNA polymerase (for example T7 RNA polymerase). When the promoter-primer is hybridized to the 3' end of the single strand of DNA a double stranded complex is formed, of which the 5' promoter sequence of the forward primer can serve as a template for an elongation reaction starting from the 3' end of the DNA strand. Thus, a double stranded promoter is formed by a DNA dependent DNA  
40 polymerase and the resulting complex can serve as template for the DNA dependent RNA polymerase to synthesize multiple copies of RNA.

In WO9104340 also several methods are disclosed to start a transcription based amplification reaction for single stranded DNA. Again, a restriction enzyme may be used to create an appropriate 3' end on the DNA, which can hybridize with a 3' sequence of a promoter primer.

- 5 In WO9104340 it is disclosed how the defined 3' end on the ssDNA may be created using a restriction enzyme that cuts ssDNA. In another embodiment of the same method, a restriction enzyme is used that cuts dsDNA, together with a restriction oligonucleotide that hybridizes to the target ssDNA and thus creates a double stranded piece of DNA that can be cut by the restriction enzyme to create the appropriate 3' end.
- 10 With this method a small piece of the restriction oligonucleotide will remain after the restriction enzyme has cut the double stranded complex. However, according to the disclosure of WO9104340, the restriction oligonucleotide is apparently chosen in such a way that after digestion, the remaining piece will be too small to stay hybridized to the 3' end of the ssDNA, and thus will fall off to make room for the promoter oligonucleotide.
- 15 However, the pre-treatment with a restriction enzyme as used with the prior art methods, although it may result in a sensitive transcription based assay, require many extra handling steps and handling time.

- 20 Hepatitis B virus (HBV) infection in humans is widespread. The virus that causes hepatitis B appears to infect only humans and chimpanzees.
- The hepatitis infection is transmitted by three general mechanisms: (1) by parenteral inoculation of infected blood or body fluids, either in large amounts as in blood transfusions or in minute amounts as through an accidental skinprick; (2) by close family or sexual contact; and (3) by some mothers, who transmit the virus to their new-born
- 25 children. Under natural conditions, HBV is not highly contagious. Transmission by inhalation occurs rarely, if ever. The transmission route through contaminated blood or blood products is a major threat to the human health.

- Infection with HBV often results in subclinical or acute self-limited liver disease or can result in chronic long-term infection. Chronic HBV infection elicits a spectrum of disease
- 30 entities ranging from the most severe form of chronic active hepatitis to less severe chronic persistent hepatitis to the asymptomatic carrier state. An array of diagnostic assays have recently been developed to aid the clinician in differentiating hepatitis B virus infections from other forms of viral hepatitis (i.e., hepatitis A, hepatitis C or hepatitis E). However, the ability to distinguish between an acute hepatitis B infection and
- 35 symptomatic chronic hepatitis B infection is still problematic. This is especially true since chronic active hepatitis and chronic persistent hepatitis patients often demonstrate a cyclic pattern of hepatitis characterized by acute exacerbation of liver injury alternating with normal liver function.

- 40 After infection with HBV, large quantities of the virus and associated particles are present in the serum. During symptomatic phases of infection, both acute and chronic HBV

patients have elevated liver enzyme levels, possess the hepatitis B surface antigen (HBsAg) in their serum, and produce antibodies to the nucleocapsid antigen (HBcAg). Antibodies specific for the HBsAg or the hepatitis B e antigen (HBeAg) are not detected. The appearance of antibody to HBsAg is usually not observed until approximately two months following disappearance of circulating HBsAg. The viral particles present in the serum are known to shed their surface coat exposing the nucleocapsid, known as the core antigen (HBcAg). Antibody production of HBcAg occurs early in the course of the acute phase of HBV infection and can persist for many years, and chronically infected patients can produce high titers of anti-HBc antibodies.

HBsAg is established as the most important marker of acute or chronic hepatitis B infection, detectable in serum of infected individuals. HBsAg screening of donor blood for example, is essential to avoid transmission of hepatitis B. It is clear that sensitivity is of utmost importance in diagnostic HBV assays.

HBV is the smallest DNA virus known, and its genome shows a highly compacted organization. A unique aspect in the replication cycle of HBV is that a pre-genomic mRNA serves as a template for the synthesis of the first viral DNA strand. The RNase H activity of the HBV DNA polymerase subsequently removes the mRNA and the complementary DNA strand is then synthesized, generating a partially double stranded DNA molecule for packaging in virions. Upon successful virus entry, the partially double stranded DNA molecule is converted into a fully double stranded DNA molecule.

HBV DNA can be detected in the blood of infected hosts who are HBsAg and HBeAg positive in more than 90% of cases. The state of the art method of measuring the quantity of infectious particles is by measuring the quantity of viral DNA in serum or plasma, because it most reliably reflects the amount of replicating virus. Several assays are available for this purpose, such as the branched DNA (bDNA) assay (Hendricks DA, Stowe BJ, Hoo BS, Kolberg J, Irvine BD, Neuwald PD, Urdea MS, Perrillo RP, 1995. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. *Am J Clin Pathol* 104: 537-546.), DNA hybridization assays and quantitative PCR (Pawlotsky JM, Bastie A, Lonjon I, Remire J, Darthuy F, Soussy CJ, Dhumeaux D, 1997. What technique should be used for routine detection and quantification of HBV DNA in clinical samples? *Journal of Virological Methods* 65: 245-253.; Zaaijer HL, ter Borg F, Cuypers HT, Hermus MC, Lelie PN, 1994. Comparison of methods for detection of hepatitis B virus DNA. *J Clin Microbiol* 32: 2088-2091.). Most of these assays, however, have only limited sensitivity.

The present invention is concerned with a transcription based amplification method including a restriction enzyme digestion. The method enables a sensitive and specific amplification (and subsequent detection) of DNA of the Hepatitis B virus. With the

method of the invention HBV DNA can be amplified and detected in a more efficient way than with prior art transcription based amplification methods. In contrast to the prior art methods the use of the restriction enzyme does not complicate the procedures used method of the invention.

5

The present invention provides a method for the transcription based amplification of a target HBV nucleic acid sequence starting from HBV DNA optionally present in a sample, comprising the steps of,

- 10 - incubating the sample, suspected to contain HBV, in an amplification buffer with one or more restriction enzymes capable of cleaving the DNA at a selected restriction site, said restriction enzyme creating a defined 3' end on one of the DNA strands, and a promoter-primer, said promoter-primer having a 5' region comprising the sequence of a promoter recognized by a DNA-dependent RNA polymerase and a 3' region
- 15 complementary to the defined 3' end of the DNA strand, a second primer, having the opposite polarity of the promoter-primer and comprising the 5' end of the target sequence, and in case of a HBV ssDNA, a restriction primer,
- 20 - maintaining the thus created reaction mixture under the appropriate conditions for a sufficient amount of time for a digestion by the restriction enzyme to take place,
- subjecting the sample to a heat treatment at a temperature and time sufficient to inactivate the restriction enzyme and/or to render at least partially a double strand single stranded,
- adding the following reagents to the sample:
- 25           an enzyme having RNA dependent DNA polymerase activity  
          an enzyme having DNA dependent DNA polymerase activity  
          an enzyme having RNase H activity  
          an enzyme having RNA polymerase activity, and
- 30 - maintaining the thus created reaction mixture under the appropriate conditions for a sufficient amount of time for the amplification to take place.

The [for an adequate amplification] necessary (appropriate) nucleoside triphosphates may be present already during the incubation step with the restriction enzyme(s), for example as part of the said amplification buffer. They may, however, be added later on

35 in the process, for example together with the enzymes after the heat treatment.

The person skilled in the art knows the enzymes used for the transcription based amplification method, and the conditions under which the transcription based amplification method is carried out and is aware of all the usual modifications that can be

40 made with regard to optimizing transcription based amplification reactions. For example, the forward primer, the promoter primer, may comprise a purine region between the

promoter sequence on the 5' end of the primer and the hybridizing sequence on the 3' end of the primer.

The sequence of the primers is largely determined by the position of the restriction site chosen.

5 The 3' end of a forward primer should anneal to the target sequence directly next to the restriction site. The primer may vary in length as long as it is sufficiently long to hybridize under the conditions used with the amplification reaction. In general the hybridizing part of the primer consists of about 10 to about 35 nucleotides.

10 Restriction primers, used in the method according to the invention if the target is HBV ssDNA, require that the overlap they show with the forward primer is minimal and the sequence of the restriction site is incorporated in such a way that the restriction enzyme actually cuts the DNA efficiently.

15 A restriction enzyme is an enzyme that can cut dsDNA at a selected site (i.e. a specific nucleotide sequence recognized by the enzyme). In selecting an appropriate restriction enzyme for the method of the invention care should be taken that a restriction site is chosen that is present in all variants of the HBV DNA (for example, a restriction site that is present in all genotypes of the hepatitis B virus, if the amplification is carried out to detect all viral HBV DNA in the sample). The restriction site should not be present in the  
20 DNA sequence in between the forward and reverse primers used.

The addition of the restriction enzyme results in the creation of a defined 3' end of the target strand of the DNA, which is then available for binding to the hybridizing part of the promoter primer. An additional aspect is that, because of the digestion, denaturation of  
25 that part of the DNA will be improved and so primer binding will be facilitated.

The promoter oligonucleotide containing the T7-promoter sequence should be designed in such a way that the hybridizing part will interact with the template directly upstream of the restriction site. The enzyme having DNA dependent DNA polymerase activity (usually a reverse transcriptase such as MMLV-RT or AMV-RT) can extend the 3' end of  
30 the target strand of the DNA created by the digestion with the restriction enzyme, using the primer as template. A double-stranded T7-promoter sequence will be formed and the production of amplicon RNA can start.

35 Surprisingly it has been found that a restriction enzyme can be used efficiently in an environment that is suitable for and adapted to a transcription based HBV DNA amplification process. In other words it has been found that the use of a restriction enzyme to cut the HBV DNA that is used as input material for a transcription based amplification, does not have to lead to complicated, additional handling of the sample. The use of the restriction enzyme is incorporated into and is part of the steps that are  
40 usually already part of the protocol for a transcription based DNA amplification.

All prior art methods describe the use of a restriction enzyme in the preparation of a DNA template for transcription based amplification as a separate pre-treatment prior to the actual transcription based amplification. Consequently the prior art use of a restriction enzyme in preparing the DNA template resulted in additional handling of the sample, like separate inactivation of the restriction enzyme and separate purification of the DNA. It complicates the whole amplification procedure, especially an automated process, and increases the risk of contamination.

Although the addition of a restriction oligonucleotide together with a restriction enzyme has already been disclosed in WO9104340, it has not been disclosed prior to the present invention how the use of the restriction enzyme (and oligonucleotide) can efficiently be combined with the transcription based amplification.

It has not been disclosed in the prior art in which way the use of restriction enzyme can be combined with transcription based amplification without additional sample handling and reagent adding steps.

The method of the invention provides this combination without complicating the prior art transcription based DNA amplification process.

The method of the invention hardly differs from a normal transcription based amplification method. The only additional step to be taken is the "built in incubation" of the sample with the restriction enzyme, which means that the restriction enzyme is used in such a way that the actual handling of the sample does not differ from a conventional / prior art transcription based DNA amplification process.

The preferred restriction enzyme used in the method of the invention is, of course, an enzyme that is relatively stable and retains a high activity under conditions where it is added to a reaction mixture comprising an amplification-buffer (which contains relatively high concentrations of salts).

After the addition of the restriction enzyme the sample needs to be incubated under the appropriate conditions for the enzyme to be active, and for a suitable amount of time.

The sample may be incubated with the restriction enzyme for a relatively short period of time, preferably for about 10 –20 minutes and more preferred for about 15 minutes at a temperature of about 35 to about 45 °C and more specifically at about 37 - 41 °C, obviously depending on the nature of the restriction enzyme used. In fact, this is the only additional measure to be taken, when compared to a conventional transcription based DNA amplification method.

The method of the invention comprises the step of heating the sample after the incubation with the restriction enzyme. During this heating the restriction enzyme is inactivated and double stranded DNA is rendered single stranded [at least partially]. This heating step is already part of the protocols for carrying out a transcription based amplification method. These methods involve a heat treatment of the sample after primer-addition, to create optimal circumstances for primer annealing (the nucleic acid is

stretched, strands or internal loops of the nucleic acid are separated, and during the cooling down, hybridization of the primers to the template is facilitated.)

The heating after the incubation with the enzyme may be done at a lower temperature of about 50 °C or higher, but is preferably carried out by way of a short incubation (about 5  
5 – 10 minutes) at a temperature above 90 °C and preferably at 95 +/- 3 °C.

Thereafter the sample may be cooled to the appropriate temperature for a transcription based amplification reaction to take place (usually about 41°C).

10 Due to the heating, at least a part of the double stranded DNA is rendered single stranded. As the primers, especially the promoter oligonucleotide, are already present prior to the heating of the sample, the heat treatment may facilitate primer annealing to DNA as well.

15 Thus, there is no need to purify the DNA from the sample after it has been subjected to a treatment with the restriction enzyme. The enzyme is simply inactivated in the heat treatment that was already part of the transcription based amplification procedure. It has been proven with the method of the invention that this is sufficient to eliminate the risk that the restriction enzyme will interfere with the actual transcription based amplification reaction.

20 After the heat treatment the additional amplification reagents for the transcription-based amplification are added in the usual way, and the transcription based amplification can be carried out in the usual way known to the skilled person

25 The amplification enzymes are only added after the heat treatment, to prevent degradation of the enzymes during the heat treatment (unless, of course, thermostable enzymes are used).

30 The major advantage of the method of the invention is that, even though that additional reagents are used (e.g. the restriction enzyme) this does not result in additional (separate) reaction steps or activities to be carried out.

35 The fact that no additional handling of the sample is required is especially important because every additional handling of the sample would increase the contamination risk, which is to be avoided at all costs, especially in amplification reactions. Moreover, if additional sample handling steps were required this would complicate automation of the method.

40 The method of the invention may also be used for single stranded DNA. When the DNA is single stranded a restriction oligonucleotide or restriction primer comprising a sequence complementary to the region including the restriction site of the target DNA is added together with the restriction enzyme.



The restriction oligonucleotide [restriction primer] hybridizes with the single stranded DNA and forms a double stranded complex that can be cut with the restriction enzyme. The addition of yet another reagent (the restriction oligonucleotide) does not result in additional steps to be carried out by the practitioner. The restriction oligonucleotide can simply be added together with the restriction enzyme and the other oligonucleotides necessary for the amplification. Thus, there is no need to open the amplification system for yet another addition of reagents.

In a preferred embodiment of the invention, the function of the restriction oligonucleotide may be incorporated in the oligonucleotide that also comprises the sequence of a promoter recognized by a DNA dependent RNA polymerase (the combined promoter and restriction -primer). In this way only two oligo's are needed for the amplification, a promoter [or forward] primer in which a sequence complementary to the target region including the restriction site has been incorporated and the second [or reverse] primer.. The sequence including the restriction site of this preferred [combined promoter and restriction] primer should preferably be allocated in such a way that:

- after digestion, the remaining part of the primer will denature from the target during the heating step
- the remaining part of the hybridizing sequence of the target is long enough for a new combined promoter and restriction primer to bind,
- Extra nucleotides surrounding the restriction site are included in the hybridization if necessary for the activity of the restriction enzyme.

Thus, a part of the combined promoter and restriction primer will now serve as restriction oligonucleotide; it will anneal to the target DNA, resulting in dsDNA comprising the restriction site recognized by the restriction enzyme. Subsequently the restriction enzyme will cut the said dsDNA, thus providing the defined 3' end on the DNA.

Preferably, an at least 1000 fold excess of this combined promoter and restriction primer with respect to the amount of target DNA should be present, as is also usual already for a conventional promoter primer in transcription based amplification reactions.

The method of the invention provides an efficient and sensitive method for the amplification and detection of viral DNA in samples suspected to contain the hepatitis B virus (HBV), especially with the HBV primers and HBV probes as described herein. Hence, these HBV primers and HBV probes represent another embodiment of the invention,

The restriction site that is selected in the method of the invention is preferably one that is conserved among the different genotypes of HBV.

Good results were obtained if the target sequence and restriction site were located in the part of the HBV genome that encodes the surface antigen.

- 5 Conserved restriction sites in the HBsAg coding region that are especially useful in the method of the invention (together with the restriction enzymes that cut at these sites) are the XbaI site located at nucleotides 247-252 according to the EcoRI site, the BssSI site located at nucleotides 253-258 according to the EcoRI site and the AvrII site located at nucleotides 178-183 according to the EcoRI site.

10

The oligonucleotide sequence of the primers is, of course, largely determined by the position of the restriction site chosen. The primer may vary in length as long as it is sufficiently long to hybridize under the conditions used with the amplification reaction. In general the hybridizing part of the primer consists of about 10 to about 35 nucleotides and more preferably of about 15 to about 30 nucleotides.

15

The 5' end of a forward primer should anneal to the target sequence directly next to the restriction site.

The position of the reverse primer is less critical, preferably it should have the sequence of a part of a conserved region sufficiently remote from the position of the forward primer to allow a probe to hybridize to the amplified target sequence in the region in between the forward and reverse primer region.

20

The preferred restriction primer is an oligonucleotide that has a minimal overlap with the forward primer, includes the sequence of the restriction site in such a way that the restriction enzyme can actually cut the dsDNA thus formed and is sufficiently long so as to hybridize with the HBV DNA in a sufficient manner.

25

Oligonucleotide forward primers which are especially useful in combination with the XbaI, AvrII and/or BssSI restriction enzymes are preferred embodiments of the invention.

Specifically, oligonucleotide sequences comprising at least 10 and preferably more than 15 nucleotides [counted from the cleavage site] of the HBV hybridizing part of SEQ ID No 1 [said hybridizing part as such being SEQ ID No 10] in combination with the restriction enzyme XbaI, of the HBV hybridizing part of SEQ ID No 2 [said hybridizing part as such being SEQ ID No 11] in combination with BssSI and/or of the hybridizing part of SEQ ID No 3 [said hybridizing part as such being SEQ ID No 12] in combination with AvrII are preferred.

30

35

Oligonucleotides which can be used as restriction primers, comprise at least 10 and preferably more than 15 nucleotides "flanking" the HBV DNA restriction site concerned and especially "flanking" the XbaI site located at nucleotides 247-252 according to the EcoRI site, the BssSI site located at nucleotides 253-258 according to the EcoRI site and  
5 the AvrII site located at nucleotides 178-183 according to the EcoRI site.

Particularly suitable restriction primers have the oligonucleotide sequences depicted in SEQ ID No. 8 and SEQ ID No 9.

Suitable probes for the detection of the amplified HBV target contain from 10 to about 35 and more preferably from about 15 to about 30 nucleotides which hybridize with the  
10 amplified HBV target and comprise at least 10 and preferably more than 15 nucleotides of the HBV hybridizing part of SEQ ID No 6 and SEQ ID No 7. (The HBV hybridizing parts of these sequences are shown in Table 1 and indicated as SEQ ID No 13 and SEQ ID No 14 respectively. The probes shown in Table 1 are further provided at both ends with non-HBV nucleotides forming entirely or sometimes together with a few HBV nucleotides  
15 the "stem" of the probe; said stem being part of the detection system chosen) .

Suitable reverse primers contain from about 10 to about 35 and more preferably from about 15 to about 30 nucleotides of a conserved region of HBV. Preferred reverse primers comprise at least 10 and preferably more than 15 nucleotides of SEQ ID No 4 and SEQ ID No 5.

20

Another embodiment of the invention is a test kit suitable for carrying out the transcription based amplification and detection of HBV DNA according to the invention comprising

- a restriction enzyme as herein described,
- a forward primer that corresponds with the cleavage site of the restriction enzyme  
25 chosen, as herein explained, and is provided with a promoter sequence,
- other reagents for carrying out a transcription based amplification reaction,
- means for detecting the amplified HBV DNA, and
- instructions for use.

## BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Schematic presentation of DNA NASBA including restriction enzyme digestion. The restriction enzyme (arrow) is only active during the initiation phase of NASBA. After digestion, the forward primer is hybridized to the template. AMV RT will extend the 3' end of the target strand (black) of the DNA, using the forward primer, including the T7 promoter sequence (dark grey) as template. The T7 DdRp will recognize the double stranded T7 promoter sequence and RNA amplicon (light grey) production will begin. The RNA amplicon sequence is complementary to the target DNA strand. During the cyclic phase, the RNA amplicon will be amplified and detected by molecular beacon technology. RNase H and the reverse primer are only required during the cyclic phase.

Figure 2: NASBA of HBV DNA with and without digestion with XbaI in combination with forward primer S-p3.8. After digestion with XbaI, S-p3.8 can be used as template for the extension of target DNA. Primer S-p4.5 is used as reverse primer and molecular beacon S-WT2 as probe. A sample without template (NT) is used as negative control.

Figure 3: NASBA of HBV DNA with and without digestion with BssSI in combination with forward primer S-p3.10. After digestion with BssSI, S-p3.10 can be used as template for the extension of target DNA. Primer S-p4.5 is used as reverse primer and molecular beacon S-WT2 as probe. A sample without template (NT) is used as negative control.

Figure 4. NASBA of HBV DNA with and without digestion with XbaI in combination with forward primer S-p3.10. S-p3.10 can not be used as template for the extension of target DNA, after digestion with XbaI. Primer S-p4.5 is used as reverse primer and molecular beacon S-WT2 as probe. A sample without template (NT) is used as negative control.

Figure 5. NASBA of HBV DNA with and without digestion with BssSI in combination with forward primer S-p3.8. S-p3.8 can be used as template for the extension of target DNA, after digestion with BssSI. Primer S-p4.5 is used as reverse primer and molecular beacon S-WT2 as probe. A sample without template (NT) is used as negative control.

Figure 6. NASBA of HBV DNA with and without digestion with AvrII in combination with forward primer S-p3.5. S-p3.5 can be used as template for the extension of target DNA, after digestion with AvrII. Primer S-p4.4 is used as reverse primer and molecular beacon S-WT4 as probe. A sample without template (NT) is used as negative control.

The invention is further exemplified by the following Examples.

**EXAMPLES:**Example 1: Amplification of HBV DNA

5 Two conserved restriction sites (XbaI and BssSI) are encoded in the conserved region (nt 244 to 285 according to the EcoRI-site) of the S-gen of HBV DNA. As this part of the S-region can be single-stranded DNA of negative polarity, an oligonucleotide ('restriction primer' (RP) complementary to the region including the restriction site sequences was added to create a double-stranded restriction site for all genomic DNAs present. HBV

10 DNA was isolated from a series of dilution of plasma infected with HBV genotype A of  $3 \times 10^9$  geq/ml, using the Nuclisens Extractor (Organon Teknika). Following the standard procedure as described for RNA isolation (Operator Manual Extractor, 41001-9, rev A, 1999), a 50  $\mu$ l extract is obtained. Five  $\mu$ l of the extract is used per assay. The restriction enzyme digestion was performed in NASBA buffer (40 mM Tris-HCl pH 8.5, 12 mM

15  $MgCl_2$ , 70 mM KCl, 15% v/v DMSO, 5 mM DTT; 1 mM each dNTP, 2 mM ATP, 2 mM CTP, 2 mM UTP, 1.5 mM GTP, 0.5 mM ITP, 0.2  $\mu$ M forward primer (S-p3.8 for XbaI, and S-p3.10 for BssSI, table 1), 0.2  $\mu$ M reverse primer (S-p4.5, table 1), 0.1  $\mu$ M molecular beacon probe (S-WT2, table 1), 0.17  $\mu$ M restriction primer (RP-3, table 1)) and 0.2 units restriction enzyme BssSI (New England BioLabs, Inc., Beverly, MA, USA) or 3.0 units

20 restriction enzyme XbaI (New England BioLabs, Inc., Beverly, MA, USA). After incubation of 15 min at 41  $^{\circ}$ C, the restriction enzymes were heat-inactivated and the DNA template denatured at 95  $^{\circ}$ C for 5 min. Hybridization of the primers occurred during cooling down to 41  $^{\circ}$ C for 3 min. Subsequently, NASBA enzymes (2.1  $\mu$ g BSA, 0.08 units RNase H, 32 units T7 RNA polymerase and 6.4 units AMV reverse transcriptase) were added, the

25 reaction mixture was mixed by gently tapping and short centrifugation, and the amplification and real-time detection was started. The reaction mixture was incubated at 41 $^{\circ}$ C in the NucliSens EasyQ Analyzer (Organon Teknika) for 120 minutes with fluorescence monitoring every minute. The reactions were excited at 485 nm and the emission signal was measured at 518 nm.

30

Example 1.1: Amplification of HBV DNA including XbaI digestion

A NASBA assay with and without the treatment with the restriction enzyme XbaI was performed. The optimal concentration of XbaI was determined under NASBA conditions

35 by digestion of  $10^9$  copies of a PCR fragment including the amplicon region of the HBV DNA, and was shown to be 3 units. S-p3.8 is used as forward primer and can be used as template by AMV RT to extend the template DNA after digestion with XbaI. Without digestion a sensitivity of  $3 \times 10^6$  geq/ml is obtained while after digestion the sensitivity is  $3 \times 10^3$  geq/ml, meaning a 1000 fold increase in sensitivity (fig. 2). In addition, without

40 digestion the time to positivity (TTP) is about 16 minutes while after XbaI digestion this is about 6 min, meaning a decrease in TTP of about 10 min (fig.2). Both are indications for an improved amplification reaction.

Example 1.2: Amplification of HBV DNA including BssSI digestion

5 A NASBA reaction, with and without treatment with the restriction enzyme BssSI was performed with the same HBV DNA extract and comparable reaction conditions as described above. The optimal concentration of BssSI was determined under NASBA conditions by digestion of  $10^9$  copies of a PCR fragment including the amplicon region of the HBV DNA, and was shown to be 0.2 units. S-p3.10 is used as forward primer and can  
10 be used as template by AMV RT to extend the template DNA after digestion with BssSI. Again significant test improvements were obtained as a result of treatment with the restriction enzyme BssSI (fig.3). Without digestion a sensitivity of only  $3 \times 10^7$  geq/ml is obtained while after digestion the sensitivity is  $3 \times 10^4$  geq/ml, meaning again a 1000 fold increase in sensitivity (fig. 3) as a result of the digestion. In addition, without digestion the  
15 time to positivity (TTP) is about 21 minutes while after BssSI digestion this is about 11 min, meaning again a decrease in TTP of about 10 min (fig.3). The results prove that the digestion of HBV DNA with a restriction enzyme prior to the NASBA reaction can considerably improve the amplification and so the detection of a HBV DNA

20

Example 1.3: Amplification of HBV DNA including XbaI digestion-2

To test if the digestion by itself or the combination of the restriction enzymes with the selected primers was the basis for the improved assay results, the assay including the XbaI digestion was repeated with primer S-p3.10 instead of S-p3.8. AMV RT can not use  
25 S-p3.10 as template to extend the target sequence after digestion with XbaI. As can be seen in figure 4, only a slight increase in sensitivity (10 fold) and small decrease in TTP (about 5 min, from 21 to 16 min) is obtained after digestion with XbaI in combination with S-p3.10. This indicates that the extension of the template during the initiation of NASBA is responsible for the improved results  
30 as obtained with XbaI and primer S-p3.8 and with BssSI and primer S-p3.10.

Example 1.4: Amplification of HBV DNA including BssSI digestion-2

To test if the extension of the target was indeed the basis for the improved assay results, the assay including the BssSI digestion was repeated with primer S-p3.8 instead of S-p3.10. AMV RT can use S-p3.8 as template to extend the target sequence after digestion with BssSI. However, after digestion with BssSI, only 17 nucleotides are included in hybridization of the primer to the target sequence while normally this is about 20 nucleotides. Despite this difference, again clear test improvements were obtained after  
40 digestion with BssSI (fig. 5). A double digestion can be performed with both XbaI and BssSI included in NASBA using the primers S-p3.8 and S-p4.5, restriction primer RT-3 and molecular beacon S-WT2 without loss of amplification efficiency as compared to the single digestion NASBA assays.

Example 1.5: Amplification of HBV DNA including AvrII digestion

The restriction site (AvrII) is encoded in another conserved region (nt 177 to 192 according to the EcoRI-site) of the S-gen of HBV DNA. Forward primer S-p3.5, reverse  
5 primer S-p4.4, molecular beacon S-WT4 and restriction primer RP-1 (table 1) were as used in NASBA. The AMV RT can extend the target strand of HBV DNA after digestion with AvrII, using S-p3.5 as template. The same reaction conditions as described above were used. A NASBA reaction, with and without treatment with the restriction enzyme  
10 AvrII was performed with the same HBV DNA extract as described above, using 2 units of AvrII per reaction. Without digestion, a sensitivity of  $> 10^8$  geq/ml is obtained while after digestion the sensitivity is  $1 \times 10^5$  geq/ml, meaning a  $>10^3$  fold increase in sensitivity (fig. 6) as a result of the digestion. Again, these results prove that the digestion of HBV DNA with a restriction enzyme digestion included in the NASBA reaction can considerably  
15 improve the amplification of HBV DNA

Table 1 Primer and probe sequences

Primer/Probe	Sequence	Label
S-p3.8 (SEQ ID No. 1)	5' <i>AATTCTAATACGACTCACTATAGGG</i> a GACTCGTGGTGGACTTCTCTCA 3'	
S-p3.10 (SEQ ID No. 2)	5' <i>AATTCTAATACGACTCACTATAGGG</i> agaa GGTGGACTTCTCTCAATTTTC 3'	
S-p3.5 (SEQ ID No.3)	5' <i>AATTCTAATACGACTCACTATAGGG</i> aga GGACCCCTGCTCGTGTTACAGGC 3'	
S-p4.5 (SEQ ID No.4)	5'GAACCAACAAGAAGATGAGGCA 3'	
S-p4.4 (SEQ ID No.5)	5'GGGACTGCGAATTTTGGCCA 3'	
S-WT2 (SEQ ID No.6)	5' <u>CGATCG</u> AGGGACTGCGAATTTTGGC <u>CGATCG</u> 3'	FAM
S-WT4 (SEQ ID No.7)	5' <u>GGATCCC</u> TIGAAAATTGAGAGAAGTCCACCAC <u>GGGATCC</u> 3'	FAM
RP-3 (SEQ ID No.8)	5'AATACCGCAGAGTCTAGACTCGTGG 3' XbaI   BssSI	3'NH <sub>2</sub>
RP-1 (SEQ ID No.9)	5'CATCAGGAYTCCTAGGA 3' AvrII	3'NH <sub>2</sub>

\*The T7-promoter sequence is written in italics, the purine-stretch in lower case, the stem sequence of the probe in underlined italics and the restriction sites are indicated.



## CLAIMS:

1. Method for the transcription based amplification of a target HBV nucleic acid  
5 sequence starting from HBV DNA optionally present in a sample, comprising the steps  
of,  
- incubating the sample, suspected to contain HBV, in an amplification buffer with one or  
more restriction enzymes capable of cleaving the HBV DNA at a selected restriction site,  
said restriction enzyme creating a defined 3' end of the said HBV DNA strand(s),  
10 a promoter-primer, said promoter-primer having a 5' region comprising the sequence of  
a promoter recognized by a DNA-dependent RNA polymerase and a 3' region  
complementary to the defined 3' end of the DNA strand,  
a second or reverse primer, having the opposite polarity of the promoter-primer and  
comprising the 5'end of the said target sequence, and  
15 in case of HBV ssDNA as the target sequence, a restriction primer,  
- maintaining the thus created reaction mixture under the appropriate conditions for a  
sufficient amount of time for a digestion by the restriction enzyme to take place,  
- subjecting the sample thus obtained to a heat treatment at a temperature and time  
sufficient to inactivate the restriction enzyme and/or to render at least partially a double  
20 strand single stranded,  
-adding the following reagents to the sample:  
    an enzyme having RNA dependent DNA polymerase activity  
    an enzyme having DNA dependent DNA polymerase activity  
    an enzyme having Rnase H activity  
25      an enzyme having RNA polymerase activity, and  
- maintaining the thus created reaction mixture under the appropriate conditions for a  
sufficient amount of time for the amplification to take place.
2. Method according to claim 1, wherein the DNA is double stranded HBV DNA.  
30
3. Method according to claim 1, wherein the DNA is single stranded and the function of  
the promoter primer and the function of the restriction primer are combined in using a  
combined promoter and restriction primer comprising a sequence complementary to the  
region including the restriction site of the target ssDNA and the sequence of a promoter  
35 recognized by a DNA-dependent RNA polymerase.
4. Method according to claim 1 in which the appropriate nucleoside triphosphates are  
added to the initial incubation mixture prior to the heat treatment.
- 40 5. Method according to claim 1 in which a reverse transcriptase is used combining the

activities of the enzyme having RNA dependent DNA polymerase activity and the enzyme having DNA dependent DNA activity.

5 6. Method according to claim 1, in which a reverse transcriptase is used having inherent RNase H activity replacing 3 enzymes, namely the enzyme having RNA dependent DNA polymerase activity, the enzyme having DNA dependent DNA activity as well as the enzyme having Rnase H activity.

10 7. Method according to claim 1, in which the incubation temperature is from 35 °C to about 45°C and preferably about 37 - 41 °C.

8. Method according to claim 1 in which to heating step is carried out at a temperature between 92 °C and 98 °C and preferably at about 95 °C.

15 9. Method according to claim 1, wherein a restriction enzyme is used that cut the HBV DNA at a site that is conserved among the different genotypes of HBV.

10. Method according to claim 1, wherein the restriction site is located in the part of the HBV genome that encodes the surface antigen.

20

11. Method according to claim 10, wherein the restriction site is an XbaI site located at nucleotides 247-252 according to the EcoRI site, the BssSI site located at nucleotides 253-258 according to the EcoRI site or an AvrII site located at nucleotides 178-183 according to the EcoRI site, and the restriction enzyme used is the XbaI , BssSI or AvrII  
25 restriction enzyme respectively.

12. Method according to claim 1, wherein the restriction primer is an oligonucleotide containing from 10 to about 35 and more preferably from about 15 to about 30 nucleotides which hybridize with the HBV target and comprise at least 10 and preferably  
30 more than 15 nucleotides "flanking" the XbaI site located at nucleotides 247-252 according to the EcoRI site, the BssSI site located at nucleotides 253-258 according to the EcoRI site or the AvrII site located at nucleotides 178-183 according to the EcoRI site.

13, Method according to claim 12, wherein the restriction primer has the oligonucleotide  
35 sequence depicted in SEQ ID No. 8 and SEQ ID No 9.

14. Method according to claim 1, wherein the promoter or forward primer is an oligonucleotide containing from 10 to about 35 and more preferably from about 15 to about 30 nucleotides which hybridize with the HBV target and comprising at least 10 and  
40 preferably more than 15 nucleotides [counted from the cleavage site] of SEQ ID No 10 in

combination with the restriction enzyme XbaI, or of SEQ ID No 11 in combination with BssSI or of SEQ ID No 12 in combination with AvrII, linked to a promoter sequence.

15 Method according to claim 14, wherein the promoter oligonucleotide has the  
5 nucleotide sequence depicted in SEQ ID 1, SEQ ID No 2, or SEQ ID No 3 respectively.

16. Method according to claim 1, wherein the amplified HBV nucleic acid is additionally  
detected using a hybridization probe comprising an oligonucleotide sequence containing  
10 from 10 to about 35 and more preferably from about 15 to about 30 nucleotides which  
hybridize with the amplified HBV target and comprise at least 10 and preferably more  
than 15 nucleotides of SEQ ID No 13 and SEQ ID No 14.

17. Method according to claim 16, wherein the probe has the oligonucleotide sequence of  
SEQ ID No 6 and SEQ ID No 7.

15 18. Method according to claim 1 wherein the second or reverse primer is an  
oligonucleotide containing from 10 to about 35 and more preferably from about 15 to  
about 30 nucleotides and comprising at least 10 and preferably more than 15  
nucleotides of SEQ ID No 4 and SEQ ID No 5.

20

19. Oligonucleotide with an nucleotide sequence selected from SEQ ID No 1 up to and  
including SEQ ID No 14

20. Set of oligonucleotide primers suitable for use in the amplification of HBV nucleic acid  
25 according to claim 1 comprising a promoter primer according to claim 14 and a reverse  
primer according to claim 18.

21. Test kit suitable for carrying out the transcription based amplification and detection of  
HBV DNA according to claim 1 comprising a restriction enzyme as herein described, a  
30 forward primer that corresponds with the cleavage site of the restriction enzyme chosen,  
as herein explained, and is provided with a promoter sequence, other reagents for  
carrying out a transcription based amplification reaction, means for detecting the  
amplified HBV DNA and instructions for use.





Figure 1



## Figure 2






Figure 3



### Figure 4



### Figure 5






Figure 6

## SEQUENCE LISTING

<110> Akzo Nobel NV

<120> Method for the amplification and detection of HBV DNA using a transcription based amplification

<130> 2001.633

<160> 14

<170> PatentIn version 3.1

<210> 1

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 1

aattctaata cgactcacta tagggagact cgtggtggac ttctctca

48

<210> 2

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 2

aattctaata cgactcacta tagggagaag gtggacttct ctcaattttc

50

<210> 3

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 3

aattctaata cgactcacta tagggagagg acccctgctc gtgttacagg c

51

<210> 4

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 4

gaaccaacaa gaagatgagg ca

22

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 5

gggactgcga attttggcca

20

<210> 6

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Probe

<400> 6

cgatcgaggg actgcgaatt ttggccgac g

31

<210> 7

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Probe

<220>

<221> misc\_feature

<222> (9)..(10)

<223> n = inosine

<400> 7

ggatccctng aaaattgaga gaagtcacc acgggatcc

39

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 8

aataccgcag agtctagact cgtgg

25

<210> 9

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 9

catcaggayt cctagga

17

<210> 10

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 10

gactcgtggt ggacttctct ca

22

<210> 11

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 11

ggtggacttc tctcaatttt c

21

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 12  
ggaccctgc tcgtgttaca ggc

23

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Probe

<400> 13  
agggactgcg aattttggcc

20

<210> 14

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Probe

<220>

<221> misc\_feature

<222> (4) .. (5)

<223> n = inosine

<400> 14

cctngaaaat tgagagaagt ccaccacg

28